Rich Receives DOD Funding to Develop Plasma Substitute

November 17, 2011 - The Department of Defense has awarded Entegrion, of which Dr. Preston Rich is Vice President and Chief Medical Officer, $43.7 million to develop a plasma-derived drug that may someday be a substitute for fresh frozen plasma.
Rich Receives DOD Funding to Develop Plasma Substitute

Dr. Preston Rich, MD, MBA, FACS, and professoro in Critical Care

Preston "Chip" Rich, MD, MBA, FACS, is Associate Professor of Surgery and Chief of the Division of Trauma/Critical Care.

To read more, see this press release from UNC Health Care, or Entegrion's news release.